Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1291583 in Patients With Bronchiectasis (Clairleafᵀᴹ)
NCT05846230Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of verducatib in bronchiectasis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment-emergent adverse events at 12 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT05846230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846230.